Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer

Model scores of the 29,894 trials active now.

Model score 8% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (136 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: patientsinhibitordiseaserecurrencetreatment
  Phrases that lowered it: clopidogrelmgproton pumpefficacyusers
• Accepts healthy volunteers: No (raises risk) · Who can join
• Primary purpose: prevention (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 19551 (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 7.9% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 6 (raises risk) · Sponsor's track record
• Sponsor's past trials: 5 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 5840 (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 70.3% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT NCT02166008 · started 2014 · scored riskier than 19% of active trials completed
• PPI and Clopidogrel Response NCT01170533 · started 2009 · scored riskier than 5% of active trials completed
• Cardio-cerebrovascular Disease and Aspirin Ulcer Relapse Evaluation NCT01051388 · started 2008 · scored riskier than 9% of active trials completed
• Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel NCT00989300 · started 2009 · scored riskier than 1% of active trials completed
• Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients NCT03362281 · started 2014 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.